Key facts
- This page summarizes Steve E. Krognes's Form 4 filing for Denali Therapeutics Inc. (DNLI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 07 Jan 2022, 17:06.
Steve E. Krognes - 05 Jan 2022 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)
- Reporting relationship
- CFO and Treasurer
- Issuer ticker
- DNLI
- Reported as of
- 05 Jan 2022
- Net transaction value
- -$99,569
- SEC form
- 4
- Accepted by SEC
- 07 Jan 2022, 17:06:05 UTC
- Prior SEC filing
- 05 Jan 2022
- Next SEC filing
- 11 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tyler Nielsen, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steve E. Krognes filed Form 4 for Denali Therapeutics Inc. (DNLI) on 07 Jan 2022.
Change
- Previous filing in this sequence was filed on 05 Jan 2022.
- Current net transaction value: -$99,569.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DNLI
transaction
Common Stock
Sale
- Transaction value
- $99,569
- Shares
- -2,225
- Change %
- -1.8%
- Price
- $44.75
- Shares after
- 124,077
- Date
- 05 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3
DNLI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 850,000
- Date
- 05 Jan 2022
- Ownership
- See footnote
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Shares sold to satisfy the tax obligations by the reporting person in connection with the settlement of previously vested restricted stock units.
Footnote F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.47 to $45.05 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Footnote F3
Includes 98,858 restricted stock units.
Footnote F4
The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.